Prevention of chemotherapy-induced neuropathy: Leukemia inhibitory factor

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1691-1693

  Van Den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBAMAZEPINE; CARBOPLATIN; CILIARY NEUROTROPHIC FACTOR; CISPLATIN; CORTICOTROPIN DERIVATIVE; DIMESNA; DOCETAXEL; FENTANYL; GABAPENTIN; GLUTATHIONE; GLYCOPROTEIN GP 130; GROWTH FACTOR; LEUKEMIA INHIBITORY FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN 3; ORG 2776; OXALIPLATIN; PACLITAXEL; PROTEASOME INHIBITOR; SOMATOMEDIN C; TAXANE DERIVATIVE; THIOL DERIVATIVE; TRAMADOL; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE; WR 2711;

AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSESTHESIA; HUMAN; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; NOTE; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEINS; TREATMENT OUTCOME;

EID: 16344383654     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0079     Document Type: Note

References (22)

1. Casey EB, Jellife AM, Quesne PML, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973;96:69-86.
2. Hilkens PHE, Planting AST, Burg MELvd, et al. Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1994;1:45-50.
3. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30:5-13.
4. Van Gerven JMA, Moll JWB, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-7.
5. Hilkens PH, Pronk LC, Verweij J, et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-22.
6. Briemberg HR, Richardson PG, Wen PY, et al. A prospective study of bortezomib-induced peripheral neuropathy [abstract]. Neuro-oncology 2004;6:371 (abstract # TA-07).
7. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG2766 in the prevention or delay of cisplatin induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997;67:172-7.
8. Cascino S, Cordella L, del ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced gluthathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32.
9. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of evidence of neuroprotective effect of amifostine. Clin Cancer Res 2004;10:461-7.
10. Verschraagen M, Boven E, Torun E, et al. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. Biochem Pharmacol 2004;68:493-502.
11. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-31.
12. Windebank AJ, Smith G, Russel JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994;44:488-94.
13. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29:87-90.
14. Gao W-Q, Dybdal N, Shinsky N, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995;38:30-7.
15. Apfel SC, Arezzo JC, Lewis ME, Kessler JA. The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice. Ann N Y Acad Sci 1993;692:243-5.
16. Davis ID, Kiers L, MacGregor L, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukaemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy induced peripheral neuropathy. Clin Canc Res 2005;11:1890-898.
17. Kilpatrick TJ, Phan S, Reardon K, Lopes EC, Cheema SS. Leukaemia inhibitory factor abrogates paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res 2001;24:163-7.
18. Ozturk G, Erdogan E, Anlar O, Kosem M, Taspinar M. Effect on leukaemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine 2005;7:31-41.
19. Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001;48:429-34.
20. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413.
21. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002;3:CD002064.
22. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.